Verrica Pharmaceuticals Aktie

Verrica Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2JPEV / ISIN: US92511W1080

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
14.08.2024 14:03:55

Why Verrica Pharma Is Rising In Pre-market?

(RTTNews) - Verrica Pharmaceuticals Inc. (VRCA) reported preliminary positive results from Part 2 of Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. All patients treated with VP-315 had a reduction in tumor size with an overall reduction of tumor size in all subjects of 86%. VP-315 was well tolerated with no reported treatment-related serious adverse events, the company said.

Ted White, CEO of Verrica, said: "We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first line therapy for use in both a primary and neoadjuvant setting. We believe VP-315 has the potential to be a multi-billion dollar commercial opportunity for Verrica."

The company expects genomic and T-cell data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA to determine next steps for the development of VP-315 for the treatment of BCC in the first half of 2025.

Shares of Verrica Pharmaceuticals are up 23% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.

Analysen zu Verrica Pharmaceuticals Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel